- Home
- BELFB vs CNTA Comparison
BELFB vs CNTA Comparison
Compare BELFB & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BELFB | CNTA |
|---|---|---|
| Founded | 1949 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BELFB | CNTA |
|---|---|---|
| Price | $171.39 | $25.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $153.75 | $37.70 |
| AVG Volume (30 Days) | 151.8K | ★ 1.6M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $649,376,000.00 | $15,000,000.00 |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | $32.22 | ★ N/A |
| Revenue Growth | 23.70 | ★ 118.88 |
| 52 Week Low | $58.00 | $9.60 |
| 52 Week High | $178.67 | $30.58 |
Technical Indicators
Market Signals| Indicator | BELFB | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 39.22 |
| Support Level | $162.18 | $25.59 |
| Resistance Level | $178.67 | $30.02 |
| Average True Range (ATR) | 7.31 | 1.29 |
| MACD | 0.07 | -0.65 |
| Stochastic Oscillator | 69.89 | 12.95 |
Price Performance
Historical ComparisonAbout BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.